Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
Inventors
Fu, Jiping • Lou, Yan • HE, Yigang
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Core Innovation
The invention features fluorinated cyclopenta[cd]indene compounds, including tetrahydro-1H-cyclopenta[cd]indene and 3-fluoro-5-substituted benzonitrile derivatives, that inhibit HIF-2α. The independent claim encompasses a method of inhibiting or relieving cancer and related conditions by administering a therapeutically effective amount of one of four specified compounds or a pharmaceutically acceptable salt thereof. The disclosed subject matter defines broad Formula (IA) and Formula (I) chemical genera, subformulae, and stereodefined deuterated analogues exhibiting inhibition potency.
The disclosure identifies cancers and other HIF-2α-mediated disease indications as treatment areas, including clear cell renal cell carcinoma, NASH, inflammatory bowel disease, pulmonary arterial hypertension, and iron-load disorders. The disclosure further describes representative pharmaceutical formulations and combination administration with radiation therapy or other anticancer agents, such as CDK4/6 inhibitors, cabozantinib, and palbociclib. Because the background section is omitted, the specific technical problem being solved is not explicitly described in patent.
Claims Coverage
The claim coverage encompasses three inventive features centered on one independent claim directed to methods of inhibiting or relieving specified cancers and related conditions.
Administration of specified fluorinated benzonitrile compounds
The independent claim covers administering a therapeutically effective amount of one of four specified fluorinated cyclopenta[cd]indene 3-fluoro-5-substituted benzonitrile derivatives, including stereochemical and deuterated forms, or a pharmaceutically acceptable salt thereof, to inhibit or relieve recited cancers and related conditions.
Combination administration with another anticancer agent
Dependent claims specify administering the claimed compound in combination with at least one other anticancer agent, including cabozantinib or palbociclib.
Targeting of renal cancer indications
Dependent claims narrow the cancer indications specifically to renal cancer and clear cell renal cell carcinoma.
The claims combine methods of inhibiting or relieving cancer using selected fluorinated cyclopenta[cd]indene compounds with dependent claim features specifying combination anticancer therapy and renal cancer indications.
Stated Advantages
The claimed method is directed to inhibiting or relieving the cancers and related conditions specified in claim 1.
Documented Applications
Inhibiting or relieving cancers and related conditions, including renal cancer, clear cell renal cell carcinoma, glioblastoma, neuroblastoma, paraganglioma, pheochromocytoma, pancreatic neuroendocrine tumors, colorectal cancer, somatostatinomas, hemangioblastomas, gastrointestinal stromal tumors, pituitary tumors, leiomyomas, leiomyosarcomas, polycythaemia, retinal cancers, von Hippel-Lindau disease, astrocytoma, lung cancer, melanoma, breast cancer, cervical cancer, head and neck cancer, ovarian cancer, prostate cancer, uterine leiomyomatosis, multiple myeloma, retinoblastoma, pancreatic endocrine tumors, squamous cell carcinoma, acute myeloid leukemia, myelodysplastic syndrome, and esophageal squamous cell carcinoma.
Treatment of other HIF-2α-mediated disease indications, including non-alcoholic steatohepatitis (NASH), pulmonary arterial hypertension, inflammatory bowel disease, and iron-load disorders.
Combination anticancer therapy administering the specified compounds with radiation therapy or at least one other anticancer agent, including CDK4/6 inhibitors, cabozantinib, and palbociclib.
Representative pharmaceutical formulations formulated for tablets, capsules, injectable, inhalation, topical, ophthalmic, and nasal administration.
Interested in licensing this patent?